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Background: The EphA2 receptor, which is expressed in many types of cancer, is activated by two different
mechanisms. Activation by engagement with one of its ephrin ligands is anti-oncogenic whereas phosphorylation
of S897 by AKT increases migration, invasion and metastasis. Down-regulation of claudin-4 (CLDN4) produces a loss
of E-cadherin and increased β-catenin signaling and a phenotype similar to that produced by oncogenic activation
of EphA2, suggesting that CLDN4 may serve to restrain the pro-oncogenic signaling of EphA2.
Results: We found that constitutive knockdown of CLDN4 was associated with a 4.5-fold increase in EphA2 mRNA
and a 2.5-fold increase in EphA2 protein which was reversible by re-expression of CLDN4. Knockdown of EphA2 blocked
the migratory phenotype induced by loss of CLDN4. Knockdown of CLDN4 resulted in a 5.8-fold increase in pEphA(S897),
the oncogenic form of the receptor, as well as partial mislocalization of the excess EphA2 to the interior of the cell. Forced
expression of E-cadherin did not reduce total EphA2 or pEphA(S897) whereas re-expression of CLDN4 restored localization
and reduced EphA2 and pEphA(S897) even in cells not expressing E-cadherin. Transient siRNA-mediated knockdown of
EphA2 and β-catenin, and inhibition of PI3K by LY294002, demonstrated that increased pEphA(S897) in the CLDN4
knockdown cells was attributable to an increase in the level of active dephospho-β-catenin upstream of PI3K and AKT.
Conclusions: We conclude that CLDN4 serves to restrain pro-oncogenic signaling from EphA2 by limiting the activity of
β-catenin and PI3K and preventing phosphorylation of EphA2 on S897 by AKT. This suggests that interventions directed
at enhancing the level or functional activity of CLDN4 may be of therapeutic interest.Background
Eph receptors make up the largest family of receptor
tyrosine kinases (RTK). There are 14 distinct Eph
receptors and they interact with 8 membrane-bound
ligands known as ephrins. There are two subfamilies of
Eph receptors, EphA and EphB. The 9 EphA receptors
expressed in humans bind 5 different glycosyl phos-
phatidylinositol (GPI)-linked ephrin-A ligands and the 5
EphB receptors bind 3 transmembrane ephrin-B ligands
[1]. EphA2 is of particular interest because it is up-
regulated in many tumors and its expression frequently
correlates with an aggressive phenotype [2-7]. One of
the unique features of the Eph/ephrin interaction is that
it generates signals that propagate in both directions; by
convention the signaling activated in the Eph-expressing
cell is considered forward signaling.* Correspondence: xlin@ucsd.edu; showell@ucsd.edu
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unless otherwise stated.EphA2 can be activated by two different mechanisms.
Activation by interaction with ephrin-A1 causes phos-
phorylation of EphA2 that generates an anti-oncogenic
signal as shown by the observation that forced activation
by exposure to soluble ephrin-A1 can inhibit tumor growth
both in vitro and in vivo [8,9]. Although ephrinA1 is
expressed at low levels in cancer cells it can robustly acti-
vate EphA2 upon release into the extracellular environment
[10]. Activation by the ephrin-independent pathway in-
volves activation of PI3K and phosphorylation of AKT
which in turn phosphorylates EphA2 on serine 897 in the
cytoplasmic tail [11]. Increasing the phosphorylation of
EphA2 in this manner generates an oncogenic signal that
results in increased EphA2-dependent cell migration and
invasion [9,11]. Thus, the signals generated by EphA2 can
be switched from anti-oncogenic to oncogenic direction
depending on how this kinase is phosphorylated, and the
net effect is the result of balance between the two activation
mechanisms. Despite its frequent over-expression on malig-
nant cells, when tumors are grown in vivo EphA2 appearsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain

























































Figure 1 Effect of CLDN4 on EphA2 expression. (A) Representative
Western blot showing that CLDN4 knockdown increased EphA2
level, and that this was partially reversed by re-expression of
CLDN4 expression. (B) The histogram shows the mean level of
EphA2 protein determined from 3 independent experiments
expressed as the fold change relative to that in the scrambled
siRNA control 2008/SCB cells after normalization to β-actin.
(C) qRT-PCR analysis showing that knockdown of CLDN4 increased
EphA2 mRNA level and that this was partially reversed by re-expression
of CLDN4. Results are given as mean ± SEM (n = 3–4). **p < 0.01 versus
2008/SCB; ##p < 0.01 versus CLDN4KD.
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the membrane of adjacent cells and thus the output in this
setting is largely oncogenic.
One of the hallmarks of malignant epithelial cells is
that the cell-cell junctions, particularly the tight junc-
tions (TJ), are disassembled, remodeled or lost [12-17].
We reported previously that knockdown of claudin-4
(CLDN4) in a human cervical cancer cell line 2008 mark-
edly increases the growth of its xenografts and enhances
their metastatic potential through down-regulation of
E-cadherin mRNA and protein levels [18]. Interestingly, it
has been demonstrated that E-cadherin promotes EphA2–
ephrin-A1 interaction at the cell–cell junctions by stabiliz-
ing intercellular contacts, which in turn enhance the
EphA2 forward anti-oncogenic signaling [9].
We report here that CLDN4 can control the switch
from the ephrin-A1-dependent anti-oncogenic to the
AKT-dependent pro-oncogenic signaling by decreasing
the phosphorylation of EphA2 at S897 through inhib-
ition of active β-catenin. Constitutive knockdown of
CLDN4 in the 2008 cells increased the amount of active
β-catenin and the pAKT(S473) and pEphA2(S897) levels
which in turn drive the AKT-EphA2 pro-oncogenic
signaling cascade in a ligand independent manner. Re-
expression of CLDN4, or forced expression of CLDN4 in
cells in which it is not endogenously expressed, was
found to restrain AKT-EphA2 pro-oncogenic signaling.
Results
CLDN4 knockdown modulates the expression of EphA2
The over-expression of EphA2 found in many aggressive
tumors is associated with increased proliferation and
migration [19,20], and this has been linked to ligand-
independent activation of EphA2 through phosphorylation
on S897 [11]. In a previous study [18] we molecularly
engineered the cervical carcinoma 2008 cell line to create
a CLDN4KD subline in which the expression of CLDN4
was constitutively knocked down as a result of infection
with a lentivirus expressing an shRNAi targeted to the
CLDN4 mRNA. The level of both CLDN4 mRNA and
protein was decreased by 80-90% compared with the par-
ental 2008 cells infected with the control virus expressing
































































































































































Figure 2 (See legend on next page.)
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Figure 2 Effect of siRNA-mediated knockdown of EphA2 on migration of 2008/SCB and CLDN4KD cells. (A) Relative motility was
determined by the ability of 2008/SCB and CLDN4KD cells with or without knockdown of EphA2 expression to close a wound made by
creating a scratch through a lawn of confluent cells. Cell images were taken at 0 and 8 h after the scratch. The histogram shows quantification
of the migration speed from two independent experiments each performed with triplicate cultures. Migration distance (μm) travelled 8 h after
the scratch was determined using Slidebook (v5.0) software and average motile speed (μm/min) was calculated. Values are the mean ± SEM;
**p < 0.01 versus 2008/SCB/siRNA-Control, ##p < 0.01 versus CLDN4KD/siRNA-Control. (B) Expression of CLDN4 and EphA2 in the indicated four
cell lines by Western blot analysis. The histogram summarizes the results of 3 independent experiments expressed as the fold change relative
to that in the scrambled siRNA control 2008/SCB cells after normalization to β-actin. Results are reported as mean ± SEM (n = 3).
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analysis was used to determine whether the aggressive
phenotype of the CLDN4KD cells was linked to changes
in the expression of EphA2. As shown in Figure 1A and
1B, knockdown of CLDN4 resulted in a 2.5 ± 0.1-fold in-
crease in total EphA2 protein (p < 0.01). To document the
specificity of this effect, CLDN4 was stably re-expressed in
the CLDN4KD cells by infecting them with a lentivirus
coding for a CLDN4 mRNA containing 6 mutations that
did not alter the amino acid sequence but abrogated rec-
ognition by the shRNAi to create the CLDN4KD/rescued
cells. Re-expression of CLDN4 partially reversed the effect
of CLDN4 knockdown and reduced total EphA2 by 35.7%
(p > 0.05) to a level of 1.6 ± 0.2 -fold above that in the con-
trol 2008/SCB cells. The change in total EphA2 induced
by knockdown of CLDN4 was accompanied by an even
larger change in EphA2 mRNA as quantified by qRT-PCR.
Figure 1C shows that CLDN4 knockdown increased
EphA2 mRNA by 4.5 ± 0.14 -fold (p < 0.01), and that
re-expression of CLDN4 partially reduced this by 63.5%
(p < 0.01) to the extent of 1.6 ± 0.16 -fold above that in the
2008/SCB cells. Thus, knockdown of CLDN4 produced
substantial increases in both EphA2 mRNA and protein
levels.
EphA2 signaling is responsible for the enhanced
migration observed in CLDN4KD cells
We previously reported that knockdown of CLDN4 in-
creased the migration, invasion and metastatic potential of
2008 cells [18]. To determine the extent to which the en-
hanced migration was mediated by EphA2, the 2008/SCB
and CLDN4KD cells were treated with scrambled siRNA
or siRNA targeted to EphA2 which reduced the level of
EphA2 protein by >50%. As shown in Figure 2, knock-
down of CLDN4 significantly increased the migration rate
whereas concomitant knockdown of EphA2 partially
reversed this effect despite the fact that the knockdown of
EphA2 was not complete. Thus, the migratory behavior of
the CLDN4KD cells was modulated by the level of EphA2.
CLDN4 knockdown alters the phosphorylation and kinase
activity of EphA2
Phosphorylation of EphA2 on S897 is believed to mediate
oncogenic signaling from this receptor. The extent of S897phosphorylation was quantified by Western blot analysis
using a phospho-S897-specific antibody. Figure 3A shows a
representative Western blot, and Figure 3B shows the re-
sults of quantification of 3 independent Western blot ana-
lyses. The results indicate that the ratio of the steady-state
level of S897 phosphorylation to total EphA2 was a 5.4 ±
0.2 times higher in the CLDN4KD cells than in the 2008/
SCB cells (p < 0.05). When CLDN4 was re-expressed, the
level of EphA2 phosphorylation on S897 in the CLDN4KD-
rescued cells was reduced by 1.8 ± 0.5 -fold (p > 0.05) as
compared with that in CLDN4KD cells. Thus, knockdown
of CLDN4 was associated with a large increase in S897
phosphorylation and this was reversed by 37.5% when
CLDN4 was re-expressed (p > 0.05).
To directly measure EphA2 activity we used a human
phospho-receptor tyrosine kinase (RTK) array capable of
simultaneously quantifying the tyrosine phosphorylation
levels of 49 different RTKs. As shown in Figure 3C, the
only RTK in this panel that demonstrated an increase in
the phosphorylation was EphA2. Figure 3D presents the
quantification and indicates that the phosphorylation of
EphA2 was 2.1 ± 0.2 -fold higher in the CLDN4KD cells
than in the 2008/SCB cells (p < 0.05). Thus, the 5.8 -fold
increase in EphA2 phosphorylation on Ser897 was
accompanied by a smaller but significant increase in its
tyrosine phosphorylation. To confirm and extend the
result of the RTK array analysis, we performed an
immunoprecipitation study to detect the relative level of
phosphotyrosine in EphA2 immunoprecipitates. As
shown in Figure 3E and 3F, an increased level of tyrosine
phosphorylation was also observed in EphA2-enriched
precipitates prepared from CLDN4KD cells as compared
with the control 2008/SCB cells.CLDN4 knockdown causes EphA2 mislocalization
In non-neoplastic epithelial cells EphA2 is reported to
be localized to sites of cell-cell contact and this is
dependent on the proper function of E-cadherin [21]. In
the absence of functional E-cadherin, EphA2 was found to
be redistributed into membrane ruffles and its localization
could be restored by re-expressing E-cadherin. Interest-
ingly, we previously found that E-cadherin expression was




















































































































Figure 3 (See legend on next page.)
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Figure 3 CLDN4 knockdown affects the phosphorylation and kinase activity of EphA2. (A) Representative Western blot showing the effect
of CLDN4 knockdown and re-expression on EphA2 Ser897 phosphorylation. (B) Histogram showing the mean ± SEM level of pEphA2-Ser897 determined
from 6 independent experiments expressed as the fold change relative to that in the scrambled siRNA control 2008/SCB cells after normalization to
β-actin. *p< 0.05 versus 2008/SCB. (C) Measurement of EphA2 kinase activity in 2008/SCB and CLDN4KD cells using a human phospho-receptor tyrosine
kinase array containing 49 different kinase substrates that include EphA1-5, EphA10 and EphB1-4, 6. (D) Quantification of the relative level of EphA2
tyrosine phosphorylation by densitometry. Results are presented as mean ± SEM (n = 3). *p < 0.05 versus 2008/SCB. (E) Detection of phosphotyrosine in
immunoprecipitates prepared by using anti-EphA2 antibodies. Immunoprecipitates were probed with pan anti-phosphotyrosine antibody conjugated
to horseradish peroxidase (HRP). (F) Histogram showing the average level of phosphotyrosine determined from 3 independent experiments expressed
as the fold change relative to that in the scrambled siRNA control 2008/SCB cells after normalization to total EphA2. Results are presented as mean ±
SEM (n = 3). *p < 0.05 versus 2008/SCB.
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ation of EphA2 localization in the CLDN4KD cells. As
shown in Figure 4A, and in Additional file 1: Figure S1
where co-staining with phalloidin was performed to iden-
tify the cell membrane, in the 2008/SCB cells EphA2 was
located at the cell surface and concentrated at cell-cell
contact sites. In the CLDN4KD cells, in addition to an
overall increase in the amount of EphA2, a fraction of it
was located in intracellular structures. Re-expression of
CLDN4 in the knockdown cells partially restored the
normal distribution of EphA2. Analysis of biotinylated cell
surface proteins did not disclose a reduction in the
amount of EphA2 in the plasma membrane in the
CLDN4KD cells, or an increase in the CLDN4KD/rescued
cells, suggesting that the excess EphA2 observed in the
Western blot analysis was associated with the increased
amount of EphA2 in an intracellular location.
E-cadherin plays a minor role in modulating the effect of
CLDN4 knockdown on EphA2
To determine whether the effect of CLDN4 knockdown
on the level of phosphorylation and localization of
EphA2 was primarily due to the loss of CLDN4, or
whether this was a secondary effect of the loss of
E-cadherin that accompanies knockdown of CLDN4,
E-cadherin was forcibly re-expressed in the CLDN4KD
cells. Figure 5A documents the decrease in E-cadherin
level when CLDN4 was knocked down, and its restor-
ation when the CLDN4KD cells were engineered to
re-express E-cadherin. As shown in Figures 5B-E, re-
expression of E-cadherin did not result in significant
changes in the levels of total EphA2 (Figure 5B and 5C)
or in pEphA2(Ser897) (Figure 5D and 5E). These results
indicate that E-cadherin was less effective than CLDN4
at restoring total EphA2 levels or shutting down the
oncogenic signaling suggesting that the effect of CLDN4
knockdown on EphA2 was not primarily due to the
associated loss of E-cadherin.
Over-expression of CLDN4 decreases oncogenic EphA2
signaling even in the absence of E-cadherin
To further isolate the regulation of EphA2 by CLDN4
from the effect of loss of CLDN4 on E-cadherin level,CLDN4 was over-expressed in the human ovarian car-
cinoma HEY cell line that does not express E-cadherin.
Figure 6A documents the increase in CLDN4 expression
in the HEY cells and Figures 6B and 6C show that this
had no significant effect on EphA2 mRNA or total protein
level. However, while CLDN4 expression did not signifi-
cantly change the level of total EphA2 protein (p > 0.05),
overexpression of CLDN4 did decrease the ratio of
pEphA2(S897) to the total (p < 0.05) (Figure 6C and 6D).
Figure 7A shows that over-expression of CLDN4 reduced
the amount of intracellular EphA2 even in the absence of
E-cadherin expression but as in the 2008/SCR cells this
was not associated with a change in the total plasma
membrane EphA2 (Figure 7B and 7C). Thus, CLDN4 can
function independently of E-cadherin to regulate EphA2
to suppress its oncogenic signaling and alter its cellular
localization. This is consistent with our prior studies
in the HEY cell line showing that increased CLDN4
suppressed both migration and invasion [18].
CLDN4 controls the switch to AKT-EphA2 pro-oncogenic
signaling via β-catenin
The loss of CLDN4 in 2008 cells is associated with
down-regulation of E-cadherin, a substantial increase in
β-catenin signaling and the level of the active dephos-
phorylated form of β-catenin in the nucleus [18]. Our
prior work has also demonstrated that loss of CLDN4
resulted in activation of the PI3K pathway as evidenced
by increased AKT phosphorylation, elevated cellular
PIP3 content and PI3K activity [22]. Thus, one route by
which loss of CLDN4 activates EphA2 may be through
the sequential activation of PI3K and AKT by β-catenin.
Alternatively, loss of CLDN4 may activate PI3K leading
to the phosphorylation of AKT and EphA2 and the sub-
sequent activation of β-catenin secondary to the onco-
genic signaling from EphA2. To distinguish between
these alternatives, we transiently knocked down EphA2
and looked for an effect on the dephosphorylated active
form of β-catenin to determine whether β-catenin was up-
stream or downstream of EphA2. As shown in Figure 8A,
there was a clear reduction in EphA2 level but no effect
on the level of active β-catenin in the CLDN4KD cells.

























































Figure 4 (See legend on next page.)
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Figure 4 Effect of CLDN4 knockdown on EphA intracellular distribution. (A) The distribution of EphA2 in the 2008/SCB, CLDN4KD and CLDN4KD/
rescued cells was visualized by immunofluorescent staining using anti-EphA2 antibody (green). Cell nuclei were counterstained with DAPI (blue).
(B) Detection of EphA2 in biotinylated plasma membrane preparations by Western blot analysis using anti-EphA2 and anti-transferrin receptor antibody
to provide a lane loading control. (C) Histogram summarizing the results of four independent Western blots.
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the level of pAKT(S473) dramatically and to a lesser ex-
tent of pEphA2(S897) but had no detectable effect on the
level of the active form of β-catenin (Figures 8B and 8C).
Both of these results suggested that the activation of PI3K
and AKT was being driven primarily by upstream β-
catenin. To confirm this, we transiently knocked down β-
catenin in the CLDN4 knockdown cells. As shown in
Figure 8D, the siRNA was very effective in reducing the
level of dephospho-β-catenin, and this resulted in a signifi-
cant decrease of pEphA2(S897) (Figure 8D and 8E). Thus,
the data is most consistent with the concept that loss of
CLDN4 results in enhanced β-catenin and activation of
PI3K and AKT upstream of EphA2 independent of effects
mediated by loss of E-cadherin.
Discussion
CLDN4 plays an important role in tight junction forma-
tion and paracellular permeability in epithelial mono-
layers. We previously discovered that CLDN4 has quite
marked effects on tumor growth rate and metastatic
potential in the human cervical carcinoma cell line 2008.
Knockdown of CLDN4 increased migration, invasion
and in vivo growth rate and metastatic colonization of
the lungs, and these effects were shown to be specific
to the loss of CLDN4 as re-expression of CLDN4 rescued
the phenotype [18]. Forced expression of CLDN4 in the
HEY cell line that does not endogenously express this pro-
tein produced similar effects. A search for the mechanism
by which CLDN4 produces such pervasive effects led us
to consider EphA2.
Increased expression of EphA2 is found in many types
of cancer and is associated with aggressive features [23].
The phosphorylation of a single serine residue in EphA2,
S897, by AKT switches on ligand-independent promo-
tion of cell migration and invasion. The switch is turned
off when the site becomes dephosphorylated upon the
binding of EphA2 to its normal ligand ephrin-A1 [11].
To determine how CLDN4 might affect EphA2 we
examined changes in EphA2 expression, location and
activity when CLDN4 was constitutively knocked down
and found that knockdown of CLDN4 produced an in-
crease in total EphA2 expression at both transcriptional
and translational level. Knockdown of CLDN4 also re-
sulted in enhanced phosphorylation at S897 and an
increase in tyrosine phosphorylation detected using a
human phospho-RTK array. It was also accompanied by
a greater amount of intracellular EphA2 in the absenceof a clear change in total plasma membrane EphA2, a
change whose significance is uncertain. All of these
effects were specific as they are variably rescued by re-
expression of CLDN4, and this effect of CLDN4 was also
observed when it was over-expressed in the HEY cell line
that does not normally express this protein. It should be
recognized that although EphA2 is reported to be a
direct transcriptional target of Raf-MARK pathways
[24,25], the exact contribution of this protein and gen-
etic regulation of its expression to the specific processes
involved to tumor formation, maintenance, and progres-
sion is extremely complex and dependent on many
factors. The molecular basis of how loss of CLDN4 regu-
lates EphA2 gene expression remains to be determined
in the future studies.
E-cadherin plays a central role in maintaining the
integrity of epithelia and the polarity of epithelial cells.
Loss of E-cadherin expression or function is common in
cancer cells and is associated with disruption of cell-cell
contacts and increased aggressive behavior and metasta-
sis [26]. E-cadherin is also an important regulator of
EphA2. E-cadherin is required for the localization of
EphA2 at cell-cell contacts and in the absence of E-
cadherin EphA2 is redistributed into membrane ruffles
where it cannot engage with membrane-bound ligand
ephrin-A1 on adjacent cells [21,26,27]. We previously
noted that knockdown of CLDN4 is accompanied by re-
duced E-cadherin expression at both mRNA and protein
levels [18], and this led us to investigate whether simply
re-expressing E-cadherin could restore normal EphA2
localization to the sites of cell-cell contact and reduce its
pro-oncogenic signaling. However, re-expression of E-
cadherin did not clearly increase the fraction of EphA2
found in the plasma membrane, and it did not signifi-
cantly reduce either total EphA2 levels or the pEphA2
(S897) level. Thus, restoring the expression of E-
cadherin by itself did not turn off the oncogenic switch
indicating the presence of an E-cadherin-independent
mechanism of EphA2 regulation by CLDN4. Further evi-
dence of such regulation by CLDN4 was provided by the
observation that expression of CLDN4 in the HEY cells
that do not express E-cadherin enhanced the localization
of EphA2 to the plasma membrane, and reduced onco-
genic signaling as evidenced by a significant reduction in
pEphA2(S897).
The normal positioning of CLDN4 at the tight junc-
tion is known to limit activation of PI3K and AKT [22]





































































































Figure 5 Re-expression of E-cadherin in CLDN4KD cells does not significantly reduce total or pEphA2-Ser897. (A) Western blot documenting
increased expression of total E-cadherin in CLDN4KD/Ecad cells. (B) Representative Western blot showing total EphA2 levels in CLDN4KD/EV and
CLDN4KD/Ecad cells. (C) The histogram shows the mean level of total EphA2 protein determined from 3 independent experiments expressed as
the fold change relative to that in the empty-vector transfected control CLDN4KD/EV cells after normalization to β-actin. (D) Representative Western
blot showing phosph-EphA2 levels in CLDN4KD/EV and CLDN4KD/Ecad cells. (E) The histogram shows the mean phospho-EphA2/total EphA2 ratio in
CLDN4KD/EV and CLDN4KD/Ecad cells determined from 3 independent experiments. The data are expressed as mean ± SEM (n = 3).





































































Figure 6 (See legend on next page.)
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Figure 6 Over-expression of CLDN4 diminishes EphA2 oncogenic signaling even in the absence of E-cadherin. (A) Western blot analysis
confirming increased expression of CLDN4 in HEY/mc-CLDN4 cells. (B) qRT-PCR analysis of the effect of CLDN4 over-expression on EphA2 mRNA
levels. (C) Representative Western blot showing the effect of over-expression of CLDN4 in HEY cells on total EphA2 protein levels and EphA2
phosphorylation. (D) The histogram shows the mean level of the protein determined from 3 independent experiments. The relative total EphA2
levels in the HEY/mc-CLDN4 cells was expressed as the fold change relative to that in the HEY/mc cells after normalization to β-actin. The extent
of EphA2 phosphorylation in the HEY/mc-CLDN4 cells was expressed as the ratio relative to that in the control HEY/mc cells after normalization
to respective total EphA2 levels. Results presented are mean ± SEM (n = 3). *p < 0.05 versus HEY/mc.
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EphA2 on S897 the activity of β-catenin would be lim-
ited. However, neither knockdown of EphA2 nor inhib-
ition of PI3K with LY294002 reduced the active form of
β-catenin suggesting that the activation of PI3K, AKT
and EphA2 was a consequence rather than the cause of
the increase in dephospho-β-catenin. This was confirmed
when knockdown of β-catenin was shown to reduce the
level of pEphA(S897) in the CLDN4 knockdown cells. At
this point the details of how CLDN4 limits β-catenin
activity remain to be worked out. However, it is of interest
that EphA2 can phosphorylate the cytoplasmic tail of
CLDN4 which decreases its integration into tight junction
and favors more malignant behavior [28]. This suggests
the possibility of an amplification loop such that small
changes in the level of pEphA2(S897) may be augmented
by the subsequent loss of CLDN4 from the tight junction
that results in further EphA2 phosphorylation.
Conclusions
Taken together, our results suggest that CLDN4 serves
to restrain the pro-oncogenic signaling of EphA2 by lim-
iting the activity of β-catenin and PI3K and preventing
phosphorylation of EphA2 on S897 by AKT. While it
should be recognized that therapeutic approach involving
enhancement of tight junction may represent a technical
challenge, this observation suggests that interventions
directed at enhancing the level or functional activity of
CLDN4 may be still of therapeutic interest.
Methods
Cells and cell culture
Human cervical carcinoma 2008 cells and human ovarian
carcinoma HEY cells were grown in RPMI 1640 medium
supplemented with 10% fetal bovine serum, 100 U/ml peni-
cillin, and 100 mg/ml streptomycin. For many years 2008
was believed to be an ovarian cancer cell line, but recent
genetic test has shown it to be identical to the ME-180
cervical carcinoma cell line [29], and testing by ATCC of
cells submitted from this laboratory has independently con-
firmed this result. The 2008 sublines of 2008-CLDN4KD-
5.5 and CLDN4KD-4 rsc, identified here as CLDN4KD and
CLDN4KD/rescued, in which CLDN4 was knocked down
[30] and the knockdown was rescued by reintroduction of
an siRNA-resistant CLDN4 construct into the CLDN4KDcells [31], and the CLDN4-expressing subline of HEY
(HEY/mc-CLDN4) plus the empty vector-transfected
control cells (HEY/mc) [22], were cultured in the same
medium as the wild type 2008 with the addition of 10
μg/ml puromycin. The GFP-E-cadherin expressing subline
of CLDN4KD (CLDN4KD/Ecad), and the empty vector-
transfected control (CLDN4KD/EV) [22] were grown in
the same medium with the addition of 400 μg/ml G418.
Quantitative real time PCR
RNA was extracted with TRIzol reagent (Invitrogen,
Carlsbad, CA). First-strand cDNA was synthesized using
SuperScript II reverse transcriptase (Invitrogen) and ran-
dom primers. Quantitative real-time PCR was performed
using the Bio-Rad iCycler iQ detection system in the
presence of SYBR Green I dye (Bio-Rad Laboratories,
Inc, Hercules, CA). β-actin was used as reference gene and
relative mRNA levels were determined using the 2(−ΔΔCt)
method. A 1-unit difference of Ct value represents a
two-fold difference in the level of mRNA.
Western blot analysis
Whole-cell lysates were prepared in RIPA lysis buffer
(Sigma-Aldrich, St. Louis, MO) with Halt Protease and
Phosphatase Inhibitor Cocktails (Thermo Scientific,
Waltham, MA) and centrifuged at 12,000 × g for 10 min
at 4°C. The supernatant was loaded on SDS-PAGE and
separated by electrophoresis. A Bio-Rad Trans-Blot sys-
tem was used to transfer the proteins to Immobilon-P
FL membranes (Millipore, Bedford, MA). Membranes
were blocked for 1 h at room temperature in Odyssey
Blocking Buffer (Li-Cor Biosciences, Lincoln, NE),
followed by incubation overnight at 4°C with specific
antibodies. The following primary antibodies were used:
T-EphA2 (Cell Signaling Technology, Danvers, MA),
p-EphA2(Ser897) (Cell Signaling Technology), p-EphA2
(594) (Cell Signaling Technology), actin (Sigma-Aldrich).
After washing 3 times for 5 min each at room temperature
in TRIS buffered saline containing 0.1% Tween-20, the
blots were incubated for 1 h at room temperature with
fluorescently labeled secondary antibody (Li-Cor Biosci-
ences) diluted 1:10,000 in the Odyssey Blocking Buffer
containing 0.1% Tween 20 and 0.02% SDS. After 3 washes
for 5 min each in TRIS buffered saline containing 0.1%
















































Figure 7 Effect of CLDN4 on the subcellular localization of EphA2 in the absence of E-caderin. (A) Upper panel, HEY/mc cells expressing
mCherry (red) stained with anti-EphA2 antibody (green). Lower panel, HEY/mc-CLDN4 cells expressing mCherry fused to CLDN4 stained with
anti-EphA2 antibody (green). Cell nuclei were counterstained with DAPI (blue). Yellow staining indicates co-localization. (B) EphA2 levels in the plasma
membrane of HEY/mC and HEY/mc-CLDN4 cells as determined by Western blot analysis of biotinylated surface proteins. (C) Histogram summarizing
the results of 3 independent Western blots. Data presented are mean ± SEM (n = 3).
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Figure 8 (See legend on next page.)
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Figure 8 Analysis of the pathway by which loss of CLDN4 activates EphA2. (A) Western blot analysis showing no changes of active β-catenin
levels when EphA2 was knocked down in the CLDN4KD cells. (B) Representative Western blot showing the level of pAkt(Ser473), pEphA2(Ser897) and
dephospho-β-catenin in the CLDN4KD cells untreated or treated with 50 μM PI3K inhibitor LY294002 for 1 h. (C) The histogram showing the mean
level of pAkt(Ser473), pEphA2(Ser897) and dephospho-β-catenin expressed as the ratio relative to that in untreated CLDN4KD cells after normalization
for their respective total protein. Results presented are mean ± SEM (n = 3). ***p < 0.001, *p< 0.05 versus untreated CLDN4KD. (D) Representative Western
blot showing that active β-catenin was increased in the CLDN4KD cells (top panel) and siRNA-mediated knockdown of β-catenin reduced the levels of
pAkt(Ser473) and pEphA2(Ser897) in the CLDN4KD cells (bottom panel). (E) Histogram showing the mean levels of pAkt(Ser473) and pEphA2(Ser897)
determined from 3 independent experiments expressed as the fold change relative to that in the scrambled siRNA transfected CLDN4KD cells after
normalization to β-actin. Results are presented as mean ± SEM (n = 3). ###p < 0.01, ##p < 0.01 versus scrambled siRNA transfected CLDN4KD.
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Odyssey Infrared Imager (Li-Cor Biosciences). The ratio
of protein levels in both experimental cell types was calcu-
lated densitometrically after normalization to the level of
β-actin and expressed as the fold change relative to the
ratio in control cells.
EphA2 immunoprecipitation (IP)
Whole-cell lysates were diluted into IP buffer (50 mM
phosphate, pH 7.2, 200 mM NaCl, 2.5 mM dithiothrei-
tol, and 0.5% n-dodecyl-β-d-maltoside) after which they
were precleared with protein A/G plus agarose beads
(Thermo Scientific; Rockford, IL) and then centrifuged
at 1200 × g for 5 min. Anti-EphA2 antibody was added
to the precleared supernatant at a dilution of 1:100 and
rotated at 4°C for 60 min after which 10 μL of protein
A/G plus agarose beads were added and the mixture was
rotated overnight at 4°C. The beads were then washed 5
times in IP buffer and bound proteins were eluted at 37°C
with 2× sample buffer (125 mM Tris, pH 6.8, 2 mM
EDTA, 6% SDS, 20% glycerol, 0.25% bromophenol blue
and 5% β-mercaptoethanol). The eluates were assessed by
Western blot analysis using pan anti-phosphotyrosine
antibody (R & D Systems, Minneapolis, MN) and anti-
EphA2 antibody (Cell Signaling Technology).
Biotinylation of plasma membrane proteins
Assay of cell surface levels of EphA2 in the 2008/SCB,
CLDN4KD, HEY/mc and HEY/mc-CLDN4 was performed
using the Cell Surface Protein Isolation kit (Thermo Scien-
tific; Rockford, IL). Cells grown to 80–90% confluence in a
145 mm plate were biotinylated, lysed and cell surface pro-
teins isolated and eluted according to the manufacturer's
instructions. The eluted proteins were subjected to Western
blot analysis with anti-EphA2 antibody with anti-transferrin
receptor used as a loading control.
Immunofluorescent microscopy
Cells were grown on polylysine-coated eight-well chamber
slides, fixed in PBS containing 4% formaldehyde at 37°C for
20 min, followed by permeabilization in PBS- 0.3% Triton
X-100 for 10 min at room temperature. After 3 washes with
PBS, the gels were blocked for 1 h at room temperature
with 3% goat serum in PBS followed by incubationovernight at 4°C with primary antibody T-EphA2 diluted
to 1:200 in the antibody dilution buffer (PBS-3% goat
serum-0.3% Triton X-100). After washing 3 times for
5 min each at room temperature in PBS, the cells were in-
cubated for 1 h at room temperature with Alexa Fluor®
488 dye (Life Technologies, Carlsbad, CA) diluted to
1:1000 in antibody dilution buffer, followed by 3 additional
washes following which the cells were mounted with Gel-
vatol mounting medium (Fisher Scientific, Pittsburgh, PA).
Images were captured using a Nikon A1R Confocal
STORM super-resolution system.Would healing/Scratch assay
Cells were grown to confluence on 12-well cell culture
plate and scratch was made through the cell monolayer
using a pipette tip. After washing with Hank’s balanced
salt solution, fresh culture medium was added and the
cells were incubated at 37°C in a humid environment
with 5% CO2. Wound closure was observed and photo-
graphed every 15 min after making the scratch to monitor
the invasion of cells into the wounded area. Slidebook
(v5.0) software was used to track cell trajectories by nuclear
position over time of 16 – 21 cells in 4 separate micro-
scopic fields in each group, and average migration speed
was calculated. The experiment was performed twice and
assayed in triplicate.Statistical analysis
All data are presented as mean ± SEM of a minimum of
3 independent experiments. Significance of differences
between groups was determined using the Student t test
or the Dukkett one-way analysis of variance (ANOVA).Additional file
Additional file 1: Figure S1. Knockdown of CLDN4 alters EphA
intracellular distribution. The distribution of EphA2 (green) in the 2008/SCB,
CLDN4KD and CLDN4KD/rescued cells was visualized by immunofluorescent
staining using anti-EphA2 antibody. Phalloidin (purple) was used to stain
actin. Red fluorescence is from the mCherry-CDLN4.Competing interests
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